J
Jean-Jacques Grob
Researcher at Aix-Marseille University
Publications - 369
Citations - 58038
Jean-Jacques Grob is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Medicine & Melanoma. The author has an hindex of 71, co-authored 310 publications receiving 45788 citations. Previous affiliations of Jean-Jacques Grob include University of Sydney.
Papers
More filters
Journal ArticleDOI
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Marie-Françoise Avril,Steinar Aamdal,Jean-Jacques Grob,Axel Hauschild,Peter Mohr,Jean Jacques Bonerandi,Michael Weichenthal,K. Neuber,T. Bieber,K. Gilde,V. Guillem Porta,J. Fra,J. Bonneterre,Philippe Saiag,D. Kamanabrou,Hubert Pehamberger,J. Sufliarsky,J. L.Gonzalez Larriba,A. Scherrer,Y. Menu +19 more
TL;DR: ORR was higher in the fotemustine arm compared to the DTIC arm in first-line treatment of disseminated melanoma, and a trend in favor of fotamustine in terms of overall survival and time to BM was evidenced.
Journal ArticleDOI
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis
Jennifer L. McQuade,Carrie R. Daniel,Kenneth R. Hess,Carmen Mak,Daniel Y. Wang,Rajat Rai,John J. Park,Lauren E. Haydu,Christine N. Spencer,Matthew Wongchenko,Stephen R. Lane,Dung Yang Lee,Mathilde Kaper,Meredith Ann McKean,Kathryn E. Beckermann,Samuel M. Rubinstein,Isabelle Rooney,Luna Musib,Nageshwar Budha,Jessie Hao-Ru Hsu,Theodore S. Nowicki,Alexandre Avila,Tomas Haas,Maneka Puligandla,Sandra J. Lee,Shenying Fang,Jennifer A. Wargo,Jeffrey E. Gershenwald,Jeffrey E. Lee,Patrick Hwu,Paul B. Chapman,Jeffrey A. Sosman,Dirk Schadendorf,Jean-Jacques Grob,Keith T. Flaherty,Dana Walker,Yibing Yan,Edward McKenna,Jeffrey J. Legos,Matteo S. Carlino,Matteo S. Carlino,Antoni Ribas,John M. Kirkwood,Georgina V. Long,Douglas B. Johnson,Alexander M. Menzies,Michael A. Davies +46 more
TL;DR: In patients with metastatic melanoma, obesity is associated with improved progression-free survival and overall survival compared with those outcomes in patients with normal BMI, and that this association is mainly seen in male patients treated with targeted or immune therapy.
Journal ArticleDOI
Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
Michele Maio,Jean-Jacques Grob,Steinar Aamdal,Igor Bondarenko,Caroline Robert,Luc Thomas,Claus Garbe,Vanna Chiarion-Sileni,Alessandro Testori,Tai-Tsang Chen,Marina Tschaika,Jedd D. Wolchok +11 more
TL;DR: The additional survival benefit of ipilimumab plus dacarbazine is maintained with twice as many patients alive at 5 years compared with those who initially received placebo plus dACarbazine.
Journal ArticleDOI
Randomised trial of interferon α-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases
Jean-Jacques Grob,Brigitte Dréno,Pauline de la Salmoniere,Michèle Delaunay,Didier Cupissol,Bernard Guillot,Pierre Souteyrand,Bruno Sassolas,Jean-Pierre Cesarini,Sylvie Lionnet,Catherine Lok,Claude Chastang,Jean Jacques Bonerandi +12 more
TL;DR: Adjuvant therapy of high-risk melanoma with low doses of interferon α-2a for 18 months is safe and is beneficial when started before clinically detectable node metastases develop.
Journal ArticleDOI
Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
Paolo A. Ascierto,David R. Minor,Antoni Ribas,Céleste Lebbé,Anne O'Hagan,Niki Arya,Mary E. Guckert,Dirk Schadendorf,Richard F. Kefford,Jean-Jacques Grob,Omid Hamid,Ravi K. Amaravadi,Ester Simeone,Tabea Wilhelm,Kevin B. Kim,Georgina V. Long,Anne-Marie Martin,Jolly Mazumdar,Vicki L. Goodman,Uwe Trefzer +19 more
TL;DR: Dabrafenib was well tolerated and clinically active in patients with BRAF(V600E/K) mut(+) MM and cfDNA may be a useful prognostic and response marker in future studies.